Agomelatine as monotherapy for major depression: an outpatient, open-label study
Jan Pecenak, Vladimir Novotny†Clinic of Psychiatry, Faculty of Medicine, Comenius University and University Hospital, Bratislava, SlovakiaVladimir Novotny† passed away on 17 April 2012Background: Agomelatine is a novel antidepressant agonist to MT1 and MT2 subtypes of melatonin...
Main Authors: | Pecenak J, Novotny V |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-10-01
|
Series: | Neuropsychiatric Disease and Treatment |
Online Access: | http://www.dovepress.com/agomelatine-as-monotherapy-for-major-depression-an-outpatient-open-lab-a14754 |
Similar Items
-
Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]
by: Pecenak J, et al.
Published: (2013-11-01) -
Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study
by: Fornaro M, et al.
Published: (2013-02-01) -
Agomelatine for postpartum depression and breastfeeding
by: Le Xiao
Published: (2021-06-01) -
A Comparative Study of Efficacy and Safety of Agomelatine and Escitalopram in Major Depressive Disorder
by: Ravi Babu. Komaram, et al.
Published: (2015-06-01) -
Efficacy and tolerability of agomelatine in the treatment of depression
by: Plesničar BK
Published: (2014-05-01)